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Introduction: Animal models currently used in osteoarthritis-associated pain research inadequately reproduce the
initiating events and structural pathology of human osteoarthritis. Conversely, intra-articular injection of collagenase
is a structurally relevant model, as it induces articular degeneration both by digesting collagen from cartilage and
by causing articular instability, thereby reproducing some of the main events associated with osteoarthritis onset
and development. Here, we evaluated if the intra-articular injection of collagenase can be an alternative model to
study nociception associated with osteoarthritis.
Methods: Osteoarthritis was induced by two intra-articular injections of either 250 U or 500 U of collagenase into
the left knee joint of adult male Wistar rats. A six weeks time-course assessment of movement- and loading-
induced nociception was performed by the Knee-Bend and CatWalk tests. The effect of morphine, lidocaine and
diclofenac on nociceptive behaviour was evaluated in animals injected with 500 U of collagenase. Joint histopathology
was scored for both doses throughout time. The expression of transient receptor potential vanilloid 1 (TRPV1) in
ipsilateral dorsal root ganglia (DRG) was evaluated.
Results: An increase in nociceptive behaviour associated with movement and loading of affected joints was
observed after intra-articular collagenase injection. With the 500 U dose of collagenase, there was a significant
correlation between the behavioural and the histopathological osteoarthritis-like structural changes developed
after six weeks. One week after injection of 500 U collagenase, swelling of the injected knee and inflammation of
the synovial membrane were also observed, indicating the occurrence of an early inflammatory reaction.
Behavioural changes induced by the 500 U dose of collagenase were overall effectively reversed by morphine and
lidocaine. Diclofenac was effective one week after injection. TRPV1 expression increased six weeks after 500 U
collagenase injection.
Conclusion: We conclude that the intra-articular injection of 500 U collagenase in the knee of rats can be an
alternative model for the study of nociception associated with osteoarthritis, since it induces significant
nociceptive alterations associated with relevant osteoarthritis-like joint structural changes.* Correspondence: sadaes@med.up.pt
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Pain associated with osteoarthritis (OA) affects about
10% of the world’s population over 60 years [1] having,
therefore, a high individual and socio-economic impact.
It is exacerbated both by movement and loading on an
affected joint [2], being the predominant reason for pa-
tients to seek medical help. Despite the relevance of pain
in this disease and the wide variety of OA animal models
available [3-5], only recently has research been focusing
on the study of nociception in animal models of OA
[6-13]. Despite inducing nociceptive responses, current
models used to mimic OA pain present significant disad-
vantages, mainly in what concerns the mechanisms of
OA onset and development [14]. Ideally, it would be de-
sirable that an experimental model could reproduce as
closely as possible the different features of a disease. It
seems reasonable to state that the development of chronic
pain in OA should not be dissociated from the structural
articular changes that occur during the onset and progres-
sion of OA. A model that comprises both the reproduction
of the initiating events and joint tissue pathology observed
in human OA as well as the induction of relevant nocicep-
tive responses that mimic patients’ main complaints, such
as increased nociception due to movement and loading on
the affected joint, would certainly be a clinically-relevant
model for the study of OA pain.
The intra-articular (i.a.) injection of collagenase is an
established model of OA that has been predominantly used
to study the mechanisms underlying structural joint dam-
age [15-17]. Histopathological alterations of the knee joint
very similar to those observed in human OA have been de-
scribed for this model, particularly in mice [18,19] and rab-
bits [20], as well as in the lumbar facet joint of rats [21].
Collagenase induces the degeneration of the articular
cartilage by directly digesting collagen from the extracellu-
lar matrix of cartilage [20], and as a consequence of articu-
lar instability due to increased joint laxity [22]. Changes in
other articular structures from which pain may originate,
such as the subchondral bone and synovial membrane
[17,19,20], are also observed, thereby reproducing some of
the main features associated with OA onset and develop-
ment in humans [23-28].
The relevance of collagen degradation and of articular
instability as features of OA, as observed in the clinical
setting, leading to histopathological alterations that highly
correlate with those described for human OA [29], make
the i.a. injection of collagenase a clinically-relevant model
for the study of OA structural pathophysiology, and a
promising alternative to study OA-associated pain.
Therefore, we aimed at determining whether i.a. colla-
genase injection in the knee could also be a good model
to study OA-associated nociception in rats by evaluating
nociception induced by movement and loading on the
affected joint. We also tested the efficacy of morphine inreversing behavioural changes with the goal of validating
them as being nociception-related, as well as the efficacy
of a local anaesthetic intra-articularly injected in the knee,
in order to demonstrate that the nociceptive behaviours
observed are indeed originated in the knee joint. Further-
more, since there seemed to be an inflammatory reaction
occurring after the injection of collagenase, we also tested
the effect of the non-steroidal anti-inflammatory drug
(NSAID) diclofenac in reversing the nociceptive changes
observed. Additionally, to determine if changes in the sen-
sory innervation of the knee could also be observed in this
model, we evaluated, in the dorsal root ganglia (DRG) from
control and collagenase-injected animals, the expression of
the transient receptor potential vanilloid 1 (TRPV1),
an ion channel whose role in nociception is widely re-
ported [30-33].Methods
Animals
Adult male Wistar rats (230 ± 30 g, Charles River Labora-
tories, Barcelona, Spain) were housed in groups of three,
with water and food ad libitum, at a constant temperature
of 22°C and controlled lighting (12 h light/12 h dark cycle).
A total of 99 animals were used in this study: 72 for behav-
ioural testing and 27 for the pharmacological evaluation, 5
per drug (15 in total) and 4 per control (12 in total).
Experimental procedures were performed in accordance
with the ethical guidelines for the study of experimental
pain in conscious animals [34], and the European Com-
munities Council Directive 86/609/EEC amended by the
Directive 2003/65/CE and were approved by the Ethical
Committee for health of Hospital de São João, Porto,
Portugal.Osteoarthritis induction
Under brief isoflurane anaesthesia (5% isoflurane for
anaesthesia induction, 2% for maintenance), an intra-
articular injection was performed with the use of a
Hamilton syringe, with a 26 G needle inserted through
the patellar ligament into the joint space of the left
knee. Animals received two injections, one on day 0 and
another on day 3, with 25 μl of either sterile saline (con-
trol group), 250 U or 500 U of type II collagenase from
Clostridium histolyticum (Sigma-Aldrich, St.Louis, MO,
USA) dissolved in saline and filtered through a 0.22 μm
membrane [20]. Animals were randomly assigned to
each group before the first injection. Doses of collage-
nase were chosen based on a previous study that
assessed nociceptive alterations in rats [35] injected
with 500 U of collagenase. We tested the same dose and
a smaller one, to evaluate if similar changes could be ob-
tained with a smaller amount of exogenous collagenase.
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Animals injected with saline, 250 U or 500 U collagenase
(72 animals; n = 24/treatment) were randomly divided in
groups that were sacrificed at different time-points: one,
two, four and six weeks after the first injection (n = 6/
group/treatment). Movement-induced nociception was
evaluated by the Knee-Bend and CatWalk tests [13] on
Day 0 (before the first injection), and at one, two, three,
four, five and six weeks after the first injection, until each
group’s endpoint. Testing was performed blindly, always
by the same experimenter. The Knee-Bend test consists in
counting the squeaks and/or struggle reactions in response
to five alternate flexions and extensions of the knee joint,
performed within the physiological limits of knee flexion/
extension. The score of the test was determined by the
type of reaction to each movement of the joint as follows:
0 - no responses to any kind of movement of the joint;
0.5 - struggle to maximal flexion/extension; 1 - struggle to
moderate flexion/extension or vocalizations to maximal
flexion/extension; 2 - vocalizations to moderate flexion/ex-
tensions. A maximal extension corresponds to placing the
knee joint in an 180° angle; a moderate extension corre-
sponds to an angle between 120° and 150°, approximately;
a moderate flexion corresponds to an angle between 45°
and 75°, approximately; a maximal flexion corresponds
to totally bending the knee joint (corresponding ap-
proximately to an angle of 30°). The sum of the animal’s
reactions, giving maximal values of 20, represents the
Knee-Bend score, an indication of the animal’s movement-
induced nociception. The contralateral knee was always tested
first, in order to avoid an increase in the contralateral score
arising from the manipulation of the injected knee. Results for
both ipsilateral and contralateral knees were presented.
For the CatWalk test, animals were placed in a glass
platform illuminated such as to reflect light only at the
points of contact of the paw with the surface, resulting
in a bright image of the paw print. Videos were ac-
quired by a camera placed under the platform. The sig-
nal intensity depended on the paw area in contact with
the platform and increased with the pressure applied by
the paw. Random frames of the videos were analysed:
three pairs of frames (one for each hind paw) with the
animal walking and three frames with the animal stand-
ing still. For each hind paw, the number and intensity
of pixels above a defined threshold were quantified
(Image J 1.37, [36]) to determine the total paw print
intensity (mean pixel intensity × number of pixels),
allowing the comparison of the area/pressure applied
by each paw. Results were expressed as the percentage
of the total ipsilateral paw print intensity (%TIPPI) in
the total intensity of both paw prints.
The CatWalk test was always performed prior to the
Knee-Bend test, to minimize the effect of manipulation
of the affected knee joint on the animals’ gait.Joint swelling
Knee diameters were measured to infer joint swelling as an
indicator of inflammation resulting from i.a. injection of
collagenase or saline. The diameter of both knees was mea-
sured with a manual calliper. Results were presented as the
difference in knee diameter (ipsilateral-contralateral).
Tissue processing
At one, two, four and six weeks after the first injection of
saline, 250 U or 500 U of collagenase, animals were per-
fused with 4% paraformaldehyde (n = 6/group/treatment).
Their ipsilateral DRG from lumbar segments L3, L4 and
L5 were dissected, post-fixed in the same fixative (four
hours) and kept in 30% sucrose with 0.01% sodium azide.
DRG were serially sliced in 12 μm sections using a cryo-
stat, with every 10th section collected in the same slide.
DRG were always cut longitudinally yielding 8 to 10 sec-
tions from each, on average. The injected knees were also
dissected, post-fixed for 72 hours and then decalcified for
8 hours in a buffer containing 7% AlCl3, 5% HCOOH and
8.5% HCl. The joints were then washed in 0.1 M phos-
phate buffer pH 7.2, and kept in 30% sucrose with 0.01%
sodium azide until they were cut. Joints were cut into two
approximately equal halves along the medial collateral
ligament in the frontal plane. Three 10 μm frozen sections
were cut from each half at 200 μm steps using a cryostat.
Histopathology
Knee joint sections were stained either with Haematoxylin
and Eosin or by the Fast Green and Safranin-O method to
evaluate the extent of the histopathological lesions. Slides
were mounted with Eukitt (Kindler GmbH & Co., Baden-
Württemberg, Germany) and images acquired with an
Axioskop-40 microscope equipped with an AxioCam-MRc5
camera (Carl Zeiss MicroImaging GmbH, Jena, Germany).
Histological scoring was performed for the medial tibial
plateau (MTP) of the three most severely affected sections
based on the Osteoarthritis Research Society International
(OARSI) recommendations for histological assessment of
osteoarthritis in the rat [37]. Using an image analysis soft-
ware (Image Pro-plus 5.0, Media Cybernetics, Rockville,
MD, USA), the following parameters were evaluated, as
fully described by Gerwin and colleagues [37] and briefly
described here:
 Cartilage matrix loss width (CMLW). The width of
the areas of complete cartilage matrix loss was
measured along the surface (0% depth), the midzone
(50% depth) and tidemark (100% depth).
 Total cartilage degeneration width (TCDW). The
total width of the area of articular cartilage affected
by any type of degenerative change was measured.
 Significant cartilage degeneration width (SCDW).
The width of the cartilage in which 50% or greater
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compromised was measured.
 Zonal depth ratio (ZDR) of lesions. The MTP was
divided into three zones in order to evaluate the
pathology of different load-bearing areas, with zone
1 being the medial edge of the joint, zone 2 the
central area of the MTP, and zone 3 adjacent to the
cruciate ligaments. The depth of cartilage degeneration
was taken at the midpoint in each of the three zones
across the tibial surface. The lesion depth ratio was
calculated by dividing the depth of the area of
degeneration by the thickness of the cartilage, from
projected cartilage surface to tidemark.
 Cartilage degeneration score (CDS). The MTP was
divided into the three different load-bearing zones, as
described for ZDR. This parameter was an evaluation
of overall cartilage pathology with chondrocyte loss
being the primary determinant of the score. Cartilage
degeneration in each zone was scored using the
following criteria: 0 - no degeneration; 1 - minimal
degeneration, 5 to 10% of the total projected cartilage
area affected by matrix or chondrocyte loss; 2 - mild
degeneration, 11 to 25% affected; 3 - moderate
degeneration, 26 to 50% affected; 4 - marked
degeneration, 51 to 75% affected; 5 - severe
degeneration, greater than 75% affected.
 Osteophytes score (OS). The largest osteophyte in
each section was measured at its thickest point. Based
on that measurement a grade was assigned: 0 -
proliferative changes, <200 μm; 1 - small, 200 to
299 μm; 2 - moderate, 300 to 399 μm; 4 - large, 400
to 499 μm; 5 - very large, >500 μm.
 Synovial membrane inflammation score (SMIS). The
number of synovial lining cell layers, the
proliferation of subsynovial tissue, and the
infiltration of inflammatory cells were evaluated
according to the following scale: 0 - no changes (one
to two layers of synovial lining cells); 1 - increased
number of lining cell layers (three to four layers)
or slight proliferation of subsynovial tissue; 2 -
increased number of lining cell layers (three to four
layers) and/or proliferation of subsynovial tissue;
3 - increased number of lining cell layers (more than
four layers) and/or proliferation of subsynovial tissue
and infiltration of few inflammatory cells; 4 -
increased number of lining cell layers (more than
four layers) and/or proliferation of subsynovial
tissue, infiltration of large number of inflammatory cells.
 Medial joint capsule repair (MJCR). The thickness of
the medial joint capsule was measured.
 Growth plate thickness (GPT). Growth plate
thickness was measured medially and laterally (two
measures/joint), midway between the centre of the
physis and the medial (medial measurement) orlateral (lateral measurement) margin. Since no
differences were observed between the medial and
lateral measurements, results were presented as an
average of both measurements.
Immunofluorescence for TRPV1
Slides containing every 10th section of ipsilateral L3, L4 or
L5 DRG of animals sacrificed one or six weeks after colla-
genase or saline injection were used for immunofluores-
cence reactions against TRPV1. DRG sections were rinsed
in 0.1 M phosphate-buffered saline (PBS; pH 7.4), followed
by PBS + 0.3% triton X (PBST), and incubated in PBST with
10% normal serum (1 h 30). Sections were then incubated
with guinea-pig anti-TRPV1 diluted in PBST + 2% normal
serum (1:250, Chemicon, Temecula, CA, USA), overnight
at room temperature. After thorough PBST washing,
sections were incubated with Alexa Fluor 568 donkey anti-
guinea-pig secondary antibody diluted in PBST + 2% nor-
mal serum (1:2,000, one hour, room temperature, Molecular
Probes, Eugene, OR, USA). Slides were then rinsed in
PBST followed by PBS, mounted with Prolong Gold Anti-
fade mounting medium (Molecular Probes) and cover-
slipped. Negative controls were performed by following
the same procedure without the primary antibody. DRG
sections were viewed using a Zeiss Imager.Z1 fluorescence
microscope (Carl Zeiss MicroImaging GmbH, Jena,
Germany) and images were acquired using an AxioCam
MRm with AxioVision 4.6 software (Carl Zeiss MicroIma-
ging GmbH, Jena, Germany) at a 100x magnification. All
neurons and all labelled cells were counted in one slide
containing every 10th section of each DRG. Data were pre-
sented as the percentage of neurons expressing TRPV1 in
L3, L4 and L5 DRG.
Pharmacological experiments
A pharmacological evaluation was performed in different
groups of animals at one, two, four and six weeks after
500 U collagenase injection using the opiate morphine,
the local anaesthetic lidocaine and the NSAID diclofenac.
Baseline values of nociception were determined before
drug administration (t = 0 minutes). To confirm that the
behavioural responses of OA animals in the CatWalk and
Knee-Bend tests were induced by nociception, we evalu-
ated if they could be reversed by a single administration of
a non-sedative dose of morphine [7]. Morphine (6 mg/mL
in saline, Labesfal, Lisboa, Portugal) was subcutaneously
(s.c.) injected in the upper dorsum in a dose of 6 mg/Kg
[7,38] (n = 5), and drug effects on both tests were assessed
30, 60, 90, 120 and 180 minutes after administration. Con-
trol animals were also injected with 500 U of collagenase
and received a s.c. injection of saline (n = 4). Behavioural
assessment was performed after 30, 60 and 120 minutes.
To determine if nociception in this model originates from
knee articular tissues, we intra-articularly injected the local
Figure 1 Inflammation index. Joint swelling assessed by
measuring knee diameters (difference between ipsilateral and
contralateral knees). Collagenase-injected animals present increased
knee diameters one week after injection. The number of animals per
group at each time-point is indicated below the graphs. An initial
number of 24 animals was used in each group. Animals were then
sacrificed at different time-points for histopathology (one, two, four
and six weeks; n = 6 per dose and per time-point). Mean ± SEM,
two-way ANOVA followed by Bonferroni post-hoc test for comparisons
between groups at each time-point. ***P <0.001, for comparisons
between control and the 500 U collagenase group.
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U of collagenase. Lidocaine (100 mg/mL in saline, Sigma)
was administered in a dose of 5 mg, in a volume of 50 μL
[7,38] (n = 5). Drug effects on both tests were assessed
after 10, 20 and 30 minutes. Control animals received an
intra-articular injection of saline (n = 4). To assess if in-
flammation occurs during the onset and/or development
of the model, we evaluated the effect of the NSAID diclo-
fenac. Diclofenac (15 mg/mL in bidistilled water, Sigma)
was administered per os (p.o.) in a dose of 30 mg/Kg
[7,38] (n = 5), and drug effects on both tests were assessed
30, 60, 90 and 120 minutes after drug administration.
Control animals were also injected with 500 U of collage-
nase and received a p.o. administration of bidistilled water
(n = 4). Data are presented as the percentage of changes in
relation to baseline values for the time-point of peak effect
for each drug and nociceptive test. Animals were ran-
domly assigned to each group and testing was performed
blindly. Post-administration time-points for behavioural
assessment were determined in preliminary experiments.
Statistics
Animals were randomly assigned to each group. Results
are presented as mean ± SEM. The normality of all data
was assessed by the Kolmogorov-Smirnov test. Behav-
ioural data for movement induced-nociception in control,
250 U and 500 U collagenase-injected groups were ana-
lysed by two-way ANOVA, for factors time and group,
followed by Bonferroni post-hoc test for multiple compari-
sons between groups; ipsilateral vs. contralateral compari-
sons in the Knee-Bend test were performed likewise. The
pharmacological data were analysed by repeated measures
ANOVA followed by Dunnett’s post-hoc test. For the his-
tological assessment, measured parameters were analysed
by one-way ANOVA followed by Tukey post-hoc test;
scored parameters were analysed by the Kruskal-Wallis
test with Dunn’s post-hoc test. Pearson’s correlation ana-
lysis was performed for data from control and 500 U
collagenase-injected animals. The expression of TRPV1
was evaluated by the Mann–Whitney test. A P-value <0.05
was accepted as statistically significant.
Results
Joint swelling
Signs of inflammation were detected after collagenase
injection, denoted by a dose dependent increase in the
difference between the ipsilateral and contralateral knee
diameter at one week, significant only for the 500 U
dose (P <0.001, Figure 1), with ipsilateral joint diameters
returning to contralateral values thereafter.
Nociceptive behaviour
The Knee-Bend (Figure 2A-C) and CatWalk (Figure 2D-E)
tests were used to evaluate loading- and movement-induced nociception following the i.a. injection of different
doses of collagenase. In both tests and at all time-
points, saline-injected control animals showed behavioural
responses similar to those observed prior to the injection
(day 0; 3.3 ± 0.3 for the ipsilateral Knee-Bend score; 51.0 ±
0.7% for the CatWalk). In collagenase-injected animals, be-
havioural changes were time-dependent, with the highest
increase in nociception being observed one week after the
first collagenase injection, and remaining higher than on
day 0 or in control animals throughout the whole period
of analysis for both collagenase doses (Figure 2). For the
250 U, ipsilateral Knee-Bend scores (Figure 2B) increased
from 3.3 ± 0.4 on day 0 to 13.1 ± 0.9 on week 1 (P <0.001),
slightly decreasing throughout time, but remaining signi-
ficantly different from the contralateral knee and control
animals until the sixth week (10.2 ± 1.7, P <0.001). For
the 500 U dose, ipsilateral Knee-Bend scores (Figure 2C)
increased from 3.2 ± 0.6 on day 0 to 15.7 ± 0.7 on week 1
(P <0.001), slightly decreasing throughout time, but re-
maining significantly different from the contralateral
knee and control animals until the sixth week (12.3 ± 1.0,
P <0.001). The increase in the ipsilateral Knee-Bend score
for the 500 U dose at week 1 was significantly higher than
the increase observed with the 250 U dose (P <0.05). The
values obtained with the 500 U remained higher than
those with the 250 U throughout time, although differ-
ences were not statistically significant. Likewise, in the
CatWalk test, the %TIPPI showed a similar pattern for
both doses, being always below the values observed on
day 0 and in control animals, although not always
Figure 2 Nociceptive behaviour. Nociception induced by movement and loading in control and collagenase-injected rats evaluated by the
Knee-Bend and CatWalk tests. Knee-Bend score (A-C) is presented for both ipsilateral and contralateral knees of saline-injected control rats (A),
and rats injected with 250 U (B) or 500 U (C) of collagenase. CatWalk data (D, E) are expressed as the percentage of total ipsilateral paw print
intensity (%TIPPI). Collagenase-injected animals present increased movement- and loading-induced nociception. The number of animals per
group at each time-point is indicated below the graphs. An initial number of 24 animals was used in each group. Animals were then sacrificed at
different time-points for histopathology (one, two, four and six weeks; n = 6 per dose and per time-point). Mean ± SEM, two-way ANOVA followed
by Bonferroni post-hoc test for comparisons between groups at each time-point. #P <0.05, ###P <0.001, for comparisons between control and the
250 U collagenase group; *P <0.05, ***P <0.001, for comparisons between control and the 500 U collagenase group.
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250 U dose the %TIPPI decreased from 49.3 ± 1.0 on day
0 to 41.9 ± 1.4 at week 1 (P <0.001), when the lowest
values were observed, slightly increasing until the sixth
week to a value of 44.4 ± 1.9, not significantly different
from control animals. For the 500 U dose (Figure 2E) the
%TIPPI decreased from 49.4 ± 0.8 on day 0 to 35.6 ± 2.4 at
week 1 (P <0.001), when the lowest values were observed,
and increased from then until week 4 (46.6 ± 1.9, n.s.), de-
creasing again until the sixth week (42.0 ± 1.5, P <0.05). As
for the Knee-Bend test, the decrease in the %TIPPI for the
500 U dose at week 1 was significantly higher than for the
250 U dose (P <0.01), with 500 U values remaining lower
at late time-points but not significantly different.
Pharmacological evaluation
The effect of an acute administration of morphine, lido-
caine and diclofenac on loading- and movement-induced
nociception was evaluated at one, two, four and six weeks
after injection of 500 U of collagenase (Figure 3), since this
was the dose that induced nociceptive changes that better
correlated with relevant histopathological alterations. All
animals showed increased nociceptive behaviour beforedrug or vehicle administration (t = 0 minutes, baseline).
The effect of a s.c. injection of saline, a p.o. administration
of bidistilled water or an intra-articular administration of
saline was evaluated in animals injected with 500 U col-
lagenase to monitor the vehicle’s effects. We obtained
similar results to those already published by our group for
the monoiodoacetate (MIA) model of OA [38], with no
changes being observed (data not shown).
Morphine was highly effective at all time-points of disease
progression in the Knee-Bend test, fully reversing the noci-
ceptive behaviour (Figure 3A, B). The maximal effect was
observed between 30 and 90 minutes after injection, starting
to revert thereafter. Thirty minutes after administration,
morphine significantly reduced the ipsilateral Knee-Bend
score (Figure 3A) by 95 ± 5% at week 1 (P <0.001), 93 ± 3%
at week 2 (P <0.001), 95 ± 4% at week 4 (P <0.001) and
97 ± 3% at week 6 (P <0.001). In the CatWalk test (Figure 3B),
morphine was effective one, two and six weeks after collage-
nase injection and maximal effect was observed from 60 to
90 minutes. Sixty minutes after administration, the %TIPPI
increased by 40 ± 15% at week 1 (P <0.01), 30 ± 10% at
week 2 (P <0.05), 7 ± 5% at week 4 (n.s.) and 42 ± 5% at
week 6 (P <0.01).
Figure 3 Pharmacological evaluation. Effect of morphine (6 mg/Kg, s.c., A, B), lidocaine (5 mg, i.a., C, D) or diclofenac (30 mg/Kg, p.o., E, F) on
movement- and loading-induced nociception assessed by the Knee-Bend (A, C, E) and the CatWalk (B, D, F) tests, at one, two, four and six weeks
after injection of 500 U of collagenase. A: Morphine effectively reversed the Knee-Bend scores at all time-points of disease progression. B:
Morphine was effective at one, two and six weeks of disease progression. C: Lidocaine effectively reversed the Knee-Bend scores at all time-points
of disease progression. D: Lidocaine was effective at two, four and six weeks of disease progression. E: Diclofenac effectively reversed the
Knee-Bend scores one week after injection. F: Diclofenac was effective one week after injection. Mean ± SEM. Repeated measures ANOVA followed
by Dunnett’s post-hoc test; *P <0.05, **P <0.01, ***P <0.001.
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tive behaviour (Figure 3C, D) at all time-points. The max-
imal effect was observed 10 minutes after injection, starting
to revert thereafter. In the Knee-Bend test (Figure 3C),
lidocaine significantly reduced the ipsilateral Knee-Bend
score by 50 ± 8% at week 1 (P <0.001), 53 ± 7% at week 2
(P <0.001,), 52 ± 9% at week 4 (P <0.05) and 62 ± 13% at
week 6 (P <0.01). In the CatWalk test (Figure 3D), lido-
caine increased the %TIPPI by 18 ± 4% at week 1, although
this was not statistically significant, 40 ± 12% at week 2
(P <0.01), 31 ± 11% at week 4 (P <0.01) and 41 ± 11% at
week 6 (P <0.01).Diclofenac, on the other hand, was only significantly ef-
fective at week 1 (Figure 3E, F). Its maximal effect oc-
curred 30 minutes after injection with a decrease of 21 ±
3% in the Knee-Bend score (P <0.05, Figure 3E) and an in-
crease of 22 ± 5 in the %TIPPI in the CatWalk test (P <0.05,
Figure 3F).
Histopathology
No histopathological damage in the knee joint could be
found in saline-injected control animals at any time-point
studied (Figure 4A). In contrast, dose- and time-dependent
alterations were observed in collagenase-injected rats,
Figure 4 Progression of histopathological changes in knee joint sections stained with Fast Green and Safranin O. A: Control animals
show unaltered articular cartilage (AC) and subchondral bone (SB). Animals injected with 250 U collagenase (B, C, D, E) show increased thinning
of the articular cartilage throughout time, along with focal chondrocyte disorganization. Animals injected with 500 U (F, G, H, I) show signs of
OA onset at week 4 (H) that further develop until week 6 (I) when extensive damage of the articular cartilage is observed. Bar: 50 μm.
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observation, not shown). At week 1, a slight superficial loss
of proteoglycan staining was observed in animals injected
with both doses of collagenase (Figure 4B, F), as well as a
high degree of a dose-dependent synovial inflammation
(Figure 5B, C). Two weeks after collagenase injection,
there was a dose-dependent thinning of the articular cartil-
age (Figure 4C, G), accompanied by focal chondrocyte
disorganization, for the 250 U dose (Figure 4C), and by
chondrocyte clustering and hypertrophy for the 500 U
dose (Figure 4G). Synovial inflammation, although lesspronounced than at week 1, was also observed, particu-
larly with the 500 U dose. At week 4, some erosion of
the articular surface was observable with the 250 U dose
(Figure 4D). With the 500 U dose further signs of OA
development were observed, such as the occurrence of
small fissures and superficial erosion of the articular
cartilage, along with chondrocyte clustering and hyper-
trophy (Figure 4H). Synovial inflammation was reduced
for both doses and some small osteophytes could be ob-
served. After six weeks, the 250 U dose induced loss of
proteoglycan staining, focal chondrocyte disorganization,
Figure 5 Synovial membrane histopathology. Images representative of the synovial membrane inflammation one week (A-C) and six weeks
(D-F) after injection of saline (A, D), 250 U (B, E) or 500 U of collagenase (C, F). An increased number of synovial lining cell layers, proliferation of
subsynovial tissue and infiltration of inflammatory cells are observed. Changes were most pronounced with the 500 U dose, one week after
injection, receding thereafter. Bar: 50 μm.
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matrix loss (Figure 4E). With the 500 U dose, clear signs of
OA development were observed: extensive damage of the
articular cartilage (Figures 4I and 6); areas of erosion with
deep cartilage matrix loss and focal areas of exposure of
the subchondral bone (Figure 6A, B); loss of proteoglycan
staining, chondrocyte loss (Figure 6B, C) or chondrocyte
clustering and hypertrophy and fissures of the cartilage
(Figure 6B, C). Cartilage collapse into the epiphysis was
also extensively observed (Figure 6C) and osteophytes
were also found; some signs of synovial inflammation
could also be observed (Figure 5E, F), although much
less pronounced than at one and two weeks.
Histopathological scoring
All measurements are presented in Figure 7. In control
animals, changes were barely observed, being shown only
when they were measurable. In collagenase-injected rats,
there was a continuous and dose-dependent progression
of OA evidenced by a higher degree of joint destruction
for the 500 U dose and throughout the time of OA devel-
opment for all parameters scored. Overall, there was a
higher loss of cartilage matrix after six weeks and with the
500 U dose, as shown by the CMLW parameter. CMLW
at the surface (0% depth, Figure 7A) was significantly en-
hanced both at four (P <0.05) and six weeks (P <0.001),reaching an average of 69 ± 8% of the superficial cartilage
showing matrix loss. Deeper areas of the cartilage were
only affected significantly six weeks after the injection of
500 U collagenase, as indicated by CMLW at the midzone
(50% depth, Figure 7B), with 26 ± 6% (P <0.001) of the
MTP width losing at least 50% of its depth. Exposure of
the subchondral bone was observed in some sections after
six weeks with the 500 U dose (Figure 6), as reflected in
the CMLW at the tidemark (100% depth, Figure 7C) that
showed that an average of 7 ± 3% of the cartilage width
was lost. The TCDW measurement (Figure 7D) showed
that cartilage degeneration, independent of the loss of the
extracellular matrix, was already observable after one week
for both doses, but continuously developed until the sixth
week, when 84 ± 7% (P <0.001) of the cartilage width of
animals injected with 500 U collagenase was affected by
changes that included loss of proteoglycan staining, chon-
drocyte clustering and hypertrophy or chondrocyte death,
and fissures (Figure 6). SCDW, which measures the areas
where at least 50% of the cartilage depth is affected by any
type of degenerative change (Figure 7E), showed the in-
creased depth of cartilage alterations throughout time,
being significant only at week 6 for the 500 U dose, when
42 ± 5% of its width was affected (P <0.05). This was
further reinforced by the ZDR of lesions (Figure 7G-I),
which showed that the average ratio of the cartilage
Figure 6 Articular cartilage degeneration six weeks after the injection of 500 U of collagenase. Extensive cartilage degeneration,
comprising areas of marked erosion with exposure of the subchondral bone (white arrowhead; A, B), loss of proteoglycan staining and cell
depletion (black arrow; B, C), chondrocyte clustering and hypertrophy (white arrow; B, C), fissures (black arrowhead; B, C) and tidemark
undulation (*; C). Bar: 50 μm.
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parameter also showed that there is a different degree of
destruction in different load bearing areas. In fact, the
ZDR of lesions was higher in zone 2 (Figure 7H), where
significant differences were already observed at week 1 for
the 500 U dose (P <0.01), further increasing to 0.79 ± 0.06
at week 6 (P <0.001). Zone 3, next to the cruciate liga-
ments, showed a ZDR of 0.56 ± 0.09 at week 6 (P <0.01,
Figure 7I), whereas in zone 1, the most medial area of the
MTP, the ZDR was 0.41 ± 0.06 at week 6 (P <0.05,
Figure 7G). The CDS, which takes into account the per-
centage of cartilage affected by any type of change, again
showed the different degree of destruction at different
load bearing areas (Figure 7J-L). Changes were significant
only after six weeks and only for the 500 U dose of collage-
nase, and most pronounced in zone 2, where the average
OA score was 2.9 ± 0.25 (out of 5, P <0.05, Figure 7K). The
development of osteophytes was observable for both dosesfrom week 4 onwards and was more pronounced six weeks
after 500 U collagenase injection, when some large osteo-
phytes could be observed (Figure 7F). Synovial inflamma-
tion (Figures 5 and 7M) was observed in control animals at
one and two weeks, probably as a reaction to the intra-
articular injection of saline. Collagenase-injected ani-
mals, however, showed a much higher degree of synovial
inflammation at week 1, particularly for the 500 U dose,
which diminished throughout time. No differences were
observed in the medial joint capsule (Figure 7N). The
growth plate thickness diminished over time, similarly to
what was observed in controls (Figure 7O).
Correlation analysis
The correlation analysis between the behavioural data and
the histopathological score as well as the knee diameter,
for both doses, at weeks 1 and 6, is shown in Table 1. This
correlation was performed with the data from the animals
Figure 7 (See legend on next page.)
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Figure 7 Histopathological scoring. Histopathological assessment of cartilage degenerative changes in the medial tibial plateau (MTP) of
control animals and animals injected with 250 or 500 U collagenase, one, two, four and six weeks after injection. The following parameters were
evaluated: cartilage matrix loss width (CMLW) measured along the surface (0% depth, A), the midzone (50% depth, B) and tidemark (100% depth,
C); total cartilage degeneration width (TCDW, D); significant cartilage degeneration width (SCDW, E); osteophyte score (OS, F); zonal depth ratio
(ZDR) of lesions at zone 1 (at the medial edge of the joint, G), zone 2 (at the centre of the MTP, H) and zone 3 (adjacent to the cruciate
ligaments, I); cartilage degeneration score (CDS) at zones 1 (J), 2 (K) and 3 (L); synovial membrane inflammation score (SMIS, M); medial joint
capsule width (MJCW, N); growth plate thickness (GPT, O). Mean ± SEM. Measured parameters were analysed by one-way ANOVA followed by
Tukey post-hoc test; scored parameters were analysed by the Kruskal-Wallis test with Dunn’s post-hoc test. *P <0.05, **P <0.01, ***P <0.001, for
comparisons between collagenase injected and control animals within each time point; +P <0.05, +++P <0.001, for comparisons between the 250
and 500 U groups within each time-point; #P <0.05, ###P <0.001, for comparisons between week 1 and week 6 within each group; ‡P <0.05,
‡‡P <0.01, ‡‡‡P <0.001, for comparisons between week 2 and week 6 within each group; †P <0.05, ††P <0.01, †††P <0.001, for comparisons
between week 4 and week 6 within each group; ¥P <0.05, ¥¥P <0.01, ¥¥¥P <0.001, between collagenase injected and control animals from a
different time point.
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results include the significant correlation observed be-
tween the Knee-Bend score and the knee diameter
(P <0.01) one week after injection for both doses. The
CatWalk test did not correlate with the knee diameter.
Some correlations were found for the Knee-Bend in the
250 U dose at both time points, namely with the TCDW
and the ZDR for zones 2 and 3. The CatWalk showed
no correlations for this dose at both time-points. For
the 500 U dose, a larger number of correlations could
be observed. At week 1, a correlation between both tests
and the CMLW 0% was observed, most significant for
the Knee-Bend test (P <0.001). This test also correlated
with the TCDW (P <0.01), the ZDR at zone 2 (P <0.01)
and with the synovial inflammation (P <0.05). At week
6, there were significant correlations between the Knee-
Bend score and most of the histopathological parameters
analysed (Table 1), namely with the CMLW at 0% depth
(P <0.01), the TCDW (P <0.01), the SCDW (P <0.01), the
ZDR at zones 2 (P <0.01) and 3 (P <0.05) and the CDS at
zones 1 (P <0.01) and 2 (P <0.01) and the SMIS (P <0.01).
CatWalk data also significantly correlated with the CMLW
at 0% depth (P <0.05), the TCDW (P <0.05) and the CDS
at zone 2 (P <0.05).
TRPV1 expression
Expression of the ion channel TRPV1 was observed in
small-sized neuronal cell bodies (Figure 8A, B), as is de-
scribed for this receptor [39]. In control animals one
week after saline injection, 29.4 ± 2.4% of DRG neurons
expressed TRPV1 (Figure 8C). At the same time-point,
animals injected with 500 U collagenase expressed TRPV1
in 31.9 ± 1.8% of DRG neurons (Figure 8C). Six weeks
after saline injection, 25.0 ± 1.4% of DRG neurons were
immunoreactive for TRPV1. In contrast, collagenase in-
jected rats showed a significantly increased expression
of TRPV1, with a value of 37.1 ± 2.2% positively labelled
neurons (P <0.01, Figure 8C). Although TRPV1 expres-
sion in 500 U collagenase-injected rats at one week was
not significantly different from controls at the sametime-point, a significant difference was obtained from
controls at six weeks (P <0.05).
Discussion
A clinically-relevant model of pain in OA should not
only induce relevant nociceptive behaviour but also
mimic as closely as possible the structural articular
changes observed in the human disease. Here, we show
that the injection of type II collagenase into the knee
joint of rats leads to the development of histopatho-
logical alterations similar to those described for human
OA [29], as had been observed in studies in the knee
joint of mice [19,40] and rabbits [20], and in the lumbar
facet joint of rats [21]. More importantly, we also show
for the first time that collagenase-injected rats have
nociceptive behaviours associated with movement and
loading on the OA joint which represent patients’ major
complaints [2].
Focal damage of the articular cartilage, centred on
load-bearing areas, is an important pathological trait of
human OA [41]. Accordingly, we observed that in 500
U collagenase-injected joints the destruction of the ar-
ticular cartilage was not homogeneous, mainly affecting
the MTP, where extensive areas of the articular cartilage
were affected by degenerative changes. The areas of
deeper degeneration were always observed in the cen-
tral part of the MTP as evidenced by the higher ZDR of
lesions in zone 2, where, on average, 79% of the cartil-
age depth was affected. These values are in line with the
CDS for each zone, which also showed that the central
area of the MTP was the most severely affected. Bone
alterations are also an important characteristic of OA.
Here, we observed the development of osteophytes, par-
ticularly for the 500 U dose after six weeks. Changes in
the bone-cartilage interface were also found, with cartil-
age collapse into the epiphysis being the most obvious.
Another important feature of human OA is its slow de-
velopment. Although a model that allows a fast develop-
ment of a disease is favourable for experimental studies, a
balance between an adequate experimental time and a rate
Table 1 Correlation analysis
Pearson correlation coefficient
One week Six weeks
250 U 500 U 250 U 500 U
vs KB CW KB CW KB CW KB CW
Knee diameter 0.768 −0.137 0.791 0.136 −0.017 0.564 −0.152 0.350
** - ** - - - - -
CMLW 0% 0.474 −0.389 0.929 −0.732 0.764 −0.436 0.808 −0.710
- - *** * * - ** *
CMLW 50% - - 0.506 −0.495 - - 0.569 −0.609
- - - - - - - -
CMLW 100% - - - - - - 0.456 −0.221
- - - - - - - -
TCDW 0.674 −0.407 0.801 −0.358 0.871 −0.341 0.853 −0.696
* - ** - ** - ** *
SCDW 0.260 −0.193 0.414 −0.005 0.516 0.109 0.880 −0.630
- - - - - - ** -
ZDR Z1 0.433 −0.536 0.331 0.034 0.452 0.068 0.487 −0.526
- - - - - - - -
ZDR Z2 0.891 −0.311 0.695 −0.328 0.747 −0.099 0.880 −0.662
*** - * - * - ** -
ZDR Z3 0.8032 0.147 0.598 −0.143 0.693 0.030 0.795 −0.453
** - - - * - * -
CDS Z1 0.259 0.010 0.340 0.019 0.604 0.011 0.8182 −0.576
- - - - - - ** -
CDS Z2 0.425 −0.079 0.543 −0.442 0.704 −0.425 0.863 −0.711
- - - - * - ** *
CDS Z3 0.434 −0.255 0.551 −0.344 0.565 −0.476 0.659 −0.491
- - - - - - - -
OS - - - - 0.179 −0.446 0.390 −0.606
- - - - - - - -
SMIS 0.341 0.004 0.611 −0.153 0.582 −0.204 0.860 −0.433
- - * - - - ** -
MJCR 0.621 0.114 0.279 0.0609 −0.190 −0.076 0.450 −0.546
- - - - - - - -
GPT 0.431 −0.106 0.592 −0.124 −0.007 0.142 0.745 −0.354
- - - - - - * -
*P <0.05, **P <0.01, ***P <0.01.
Pearson’s correlation analysis between Knee-Bend score or %TIPPI and knee diameter or the histopathology score parameters at one and six weeks for 250 U and
500 U collagenase-injected animals. CDS, Cartilage degeneration score; CMLW, Cartilage matrix loss width; GPT, Growth plate thickness; MJCR, Medial joint capsule
repair; OS, Osteophytes score; SCDW, Significant cartilage degeneration width; SMIS, Synovial membrane inflammation score; TCDW, Total cartilage degeneration
width; ZDR, Zonal depth ratio.
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the clinical progression of OA is desirable. In the collage-
nase injection model there is a slow and continuous evolu-
tion of the disease. The first relevant signs of cartilage
damage were only observable two weeks after injection,
and changes consistent with the development of mild OAwere first observed at the fourth week. Significant alter-
ations matching the description of human OA [29] were
observed after six weeks. In MIA-induced OA, the cur-
rently most used model of OA pain, the immediate histo-
pathological effects are more dramatic, leading to total
loss of chondrocytes just two weeks after injecting 2 mg of
Figure 8 TRPV1 expression. Transient receptor potential vanilloid 1
(TRPV1) expression was evaluated in the L3, L4 and L5 ipsilateral
dorsal root ganglia (DRG) of control and 500 U collagenase injected
rats. (A, B) TRPV1 expressed in small-sized L4 DRG neurons of control rats
(A) and 500 U collagenase-injected rats (B), six weeks after injection.
C: Six weeks after the injection of 500 U of collagenase there is an
increase in the expression of TRPV1. Mean ± SEM. **P <0.01, significantly
different from control rats at the same time-point. ¥P <0.05, significantly
different from control rats at a different time-point.
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pathological changes are typical of OA [14]. Fast chondro-
cyte depletion is a major disadvantage of the MIA model,
since chondrocytes actually play a key role in OA develop-
ment [43-45]. In fact, it has been shown that little tran-
scriptional similarity exists between rat MIA-induced OA
and human OA-derived cartilage [46], probably due to the
extensive chondrocyte death associated with the fast pro-
gression of OA in the MIA model. So, even though robust
nociceptive responses can be quickly obtained with the
MIA model, its structural progression does not reproduce
OA-like changes as satisfactorily.
One of the key steps in cartilage breakdown during hu-
man OA is the loss of type II collagen, characteristic of
articular cartilage and one of the main macromolecules of
its extracellular matrix [26-28]. Its degradation occurs
through the action of matrix metalloproteinases (MMP)
with collagenase action, which can be produced by chon-
drocytes [47]. Accordingly, MMP-13 is overexpressed in
OA patients [48] and research has been focusing on
the possibility of using MMP inhibitors for OA treatment
[49-51]. Additionally, transgenic mice expressing MMP-13
in the articular cartilage develop structural changes very
similar to human OA [52], and increased type II collagen
degradation was observed in spontaneous OA in Hartley
guinea-pigs [53]. In the collagenase model there is a better
correlation with what has been described for human OA
and spontaneous models of OA, since collagenase can alsodigest collagen from the extracellular matrix of articular
cartilage [20], rendering it susceptible to degradation.
Joint laxity is a well-known risk factor for the develop-
ment of OA in humans [23-25]. It has been shown that
i.a. injection of collagenase leads to increased joint laxity
[22] probably as a consequence of the degradation of
collagen from menisci and articular ligaments, suggest-
ing that, in this model, OA develops as a consequence of
joint instability [18,40], therefore reproducing an import-
ant trait of human OA. Surgical models of OA can also
induce histological and behavioural alterations as a con-
sequence of joint instability [7,8,54]. However, it is ne-
cessary to open the joint capsule and cut the ligaments
to induce instability, involving an aggressive destruction
of joint structures, reproducing a subset of OA develop-
ing as a consequence of traumatic knee injury. In the
collagenase model, joint instability is induced by i.a. in-
jection, a simple, non-aggressive method, with little side-
effects, which is an advantage of this model.
It seems that the collagenase model of OA can be a
relevant alternative model for the study of OA, with a
closer reproduction of its cause, its rate of progression
and its structural changes. Since our main objective was
to evaluate the applicability of a structurally relevant
model of OA to study OA-associated pain, we evaluated
whether it induces relevant nociceptive changes by
assessing nociception associated with movement and
loading on the knee joint. We found that both doses of
collagenase induced a significant increase in the noci-
ceptive behaviour, with the 500 U dose better correlating
with the histopathological changes.
Movement-induced nociception peaked during the dis-
ease onset. This was probably due to an inflammatory re-
action to collagenase injection [18-20], as is suggested by
the increase in the ipsilateral knee diameter one week after
collagenase injection, which significantly correlates with
the nociceptive changes. Furthermore, both doses of colla-
genase led to an increase in the synovial membrane in-
flammation score. This increase was more pronounced
with the 500 U dose, with a significant correlation being
observed between the degree of synovial membrane in-
flammation and the nociceptive behaviour. The inflamma-
tory cells infiltrating the synovial membrane will most
likely release pro-inflammatory mediators that may act on
the primary afferent nerve endings innervating the syn-
ovial membrane. This reaction may explain the observed
increase in nociception at early time-points. This hypoth-
esis is sustained by the observation that the NSAID diclo-
fenac significantly diminished the nociceptive behaviour at
this time point, losing its efficacy at later time-points,
when synovial membrane inflammation has receded.
At the sixth week, when the disease is fully established,
movement-induced nociception was significantly different
from controls in both nociceptive tests. At this time-point,
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movement and loading on the joint and the degree of ar-
ticular changes was also evident with the 500 U dose. The
Knee-Bend test highly correlated with both the width and
depth of lesions, as well as with the overall degeneration
assessed by the CDS. In the Knee-Bend test there is an in-
duced movement of the affected joint and rats’ reactions
are scored. In the CatWalk test, on the other hand, changes
observed are due not only to nociception arising from
loading on the affected knee joint, but also reflect their
protective behaviour of placing less weight on the affected
joint. This difference could probably account for the less
robust correlation seen between this test and the histo-
logical scores. Nevertheless, a significant correlation is ob-
served between the %TIPPI for the 500 U dose and the
CMLW at 0% depth and the TCDW, as well as with the
CDS in zone 2, the most affected area. The magnitude of
nociceptive changes was higher for the 500 U dose, even
though they were not significantly different from those in-
duced by the 250 U dose. Nevertheless, histopathological
changes were much more pronounced for the 500 U dose
and had a higher correlation with the behavioural data.
Hence, although the 250 U dose effectively induces noci-
ceptive changes, it is not as effective in inducing structural
changes. Since the 500 U dose of collagenase induced a set
of relevant osteoarthritic-like degenerative changes and
correlatable movement-induced nociceptive behaviours six
weeks after injection, this was the chosen dose for subse-
quent studies.
Overall, we hypothesize that during the development of
the disease in this model there is a balance between noci-
ception arising from an early inflammatory reaction in the
first time-points and nociception resulting from the articu-
lar damage at later time points. One could speculate that
the steady level of nociception reached after the initial
time-points can result from a progressive reduction in in-
flammation that is counterbalanced by increased joint de-
struction. The behavioural profile of rats injected with
collagenase is very similar to what we had previously ob-
served for the MIA model of OA [13]. The main difference
was in the magnitude of changes in the CatWalk test,
which were less pronounced in the collagenase model,
probably due to the fast depletion of articular cartilage and
consequent extensive bone exposure that is seen after in-
jection of 2 mg of MIA [42]. To our knowledge, only one
study had addressed nociception in the collagenase model
in rats [35]. Using the von Frey and Hargreaves tests, the
authors showed that 500 U collagenase injection in the
knee of rats leads to the development of mechanical allo-
dynia and thermal hyperalgesia. However, both tests meas-
ure referred nociception induced by paw stimulation.
Here, we used the Knee-Bend and CatWalk tests to evalu-
ate nociception induced by movement and loading on the
affected joint, a more clinically-relevant approach to assessOA-related nociception [13], since it reproduces the major
complaint of OA patients.
The efficacy of morphine, in a non-sedative dose [7], in
reversing the nociceptive behaviours induced by 500 U of
collagenase in both tests, demonstrates that these are, in
fact, nociception dependent. This is particularly relevant
in the CatWalk test, in which the differences in weight dis-
tribution between the hind limbs could otherwise be at-
tributed to the induction of joint instability rather than
nociception. The fact that morphine can reverse the
changes observed in the %TIPPI at the sixth week shows
that there is indeed a decreased loading on the affected
joint due to nociception.
The effect of the intra-articular injection of the local
anaesthetic lidocaine in diminishing the nociceptive be-
haviour evaluated by the Knee-Bend and CatWalk tests
demonstrates that there is nociceptive input arising
from the knee joint. Similar results have also been ob-
served by our group in the MIA model of OA [38].
However, since lidocaine did not fully revert nociceptive
changes, it is likely that other mechanisms may be in-
volved, such as, for example, ectopic firing of neurons
or central sensitization, that are worth being pursued in
future studies.
The expression of TRPV1 was evaluated in L3, L4 and
L5 DRG, where the majority of the cell bodies of sensory
neurons innervating the joint are located [55]. TRPV1
is selectively expressed in nociceptors [39], being a key
molecule in nociceptive pathways that can be activated
and/or sensitized by a myriad of molecules [33]. It has
been associated with nociception arising from both in-
flammatory and neuropathic conditions [30-32] and an
increased expression of this channel has also been re-
ported for the MIA model of OA [56]. Here, we show
that there is an increased expression of TRPV1 after in-
jection of collagenase. Interestingly, a slight increase is
also observed in control animals one week after saline
injection, when compared with six-week controls, which
can be explained by the small inflammatory reaction in-
duced by the injection procedure per se. Nevertheless,
the increase in collagenase-injected animals is higher.
One week after collagenase injection, TRPV1 is already
up-regulated. This increase is significantly higher than
six-week controls, even though it is not significantly
higher than the change observed in control rats at the
same time-point. Six weeks after collagenase injection,
the increase in TRPV1 expression is further enhanced,
being significantly higher than control animals at the
same time-point, similarly to what happens in the MIA
model [56]. TRPV1 up-regulation in this model shows
that changes in primary afferent neurons occur after the
development of the disease, providing further evidence
of the applicability of this model to the study of nocicep-
tion associated with OA.
Adães et al. Arthritis Research & Therapy 2014, 16:R10 Page 16 of 17
http://arthritis-research.com/content/16/1/R10Conclusion
The different induction methods of animal models of OA
seem to lead to distinct outcomes in both joint structural
damage and nociception. Since OA itself is a highly het-
erogeneous condition [57], a better understanding of pain
in this disease will certainly be obtained more effectively
by using distinct animal models. The collagenase model
combines the advantage of inducing OA as a consequence
of joint instability and degradation of collagen in the ar-
ticular cartilage, with the methodologically simple i.a. in-
jection. We show that the injection of a dose of 500 U of
collagenase in the rat’s knee leads, after six weeks of disease
progression, to a set of both histopathological and nociceptive
changes that are consistent with the development of OA-like
alterations, along with changes in the sensory innervation
of the affected joint. We, therefore, conclude that this
model may be a relevant alternative for the study of pain in
OA, complementing the currently available animal models.
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